Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Mol Genet Metab. 2016 Aug 24;119(3):278–283. doi: 10.1016/j.ymgme.2016.08.006

Table 3.

Prodromal Symptoms Experienced by Participants

Symptoms Number of Patients Reporting Symptom (%)

Pain 12 (75%)
 Generalized body, back, and neck 8 (50%)
 Bone 2 (13%)
 Knee 1 (6%)
 Chest 1 (6%)

Brain fog (cloudy, confused, distracted, disoriented, difficulty focusing, memory issues) 8 (50%)

Irritability 7 (44%)

Extreme fatigue 6 (38%)

Anxiety/agitation 5 (31%)

Headache 4 (25%)

Sleep pattern changes 4 (25%)
 Insomnia 3 (19%)
 Increased amount of sleep 1 (6%)

Weakness/numbness in extremities 3 (19%)

Altered bowel movements 3 (19%)

Abdominal swelling/distention 3 (19%)

Personality changes 3 (19%)

Nausea 3 (19%)

Each attack is different 3 (19%)

Dark urine 2 (13%)

Decreased fine motor skills 2 (13%)

Muscle weakness 2 (13%)

Burning during urination 1 (6%)

“Spiking” blood pressure 1 (6%)

Skin sensitivity 1 (6%)

Feeling of “fullness” 1 (6%)

Chest pressure 1 (6%)

Appetite changes 1 (6%)

Restlessness 1 (6%)